Microcap Ledger Lexaria Bioscience Corp. $LEXX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Kelowna, British Columbia, Canada
- Fiscal year end
- August 31
- Shares outstanding
- 24,787,446 [10-Q 2026-07-13]
What the company doesAI summary of filing
Lexaria Bioscience Corp. is a biotechnology company that develops DehydraTECH, a patented drug delivery technology that combines active pharmaceutical ingredients with fatty acid-rich oils to improve bioavailability and oral delivery. The company is pre-revenue and operates primarily through licensing its technology to third parties across multiple sectors including pharmaceuticals, nutraceuticals, and consumer products. Lexaria has licensed DehydraTECH to companies for use with various active ingredients including GLP-1/GIP drugs, cannabinoids, nicotine, vitamins, and antivirals, generating revenue through license fees and royalties. The company is also conducting its own research and development programs, having spent $8.2 million on R&D in fiscal 2025, with a focus on clinical studies of DehydraTECH-enhanced GLP-1/GIP formulations for diabetes and weight loss, and DehydraTECH-CBD for hypertension treatment. [10-K 2025-11-28]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 9 months to May 2026 | $20.0K | −$5.04M | −$4.78M | $3.50M | [10-Q 2026-07-13] |
| FY ended Aug 2025 | $705.9K | −$11.90M | −$10.45M | $1.80M | [10-K 2025-11-28] |
| FY ended Aug 2024 | $464.3K | −$5.80M | −$4.96M | $6.50M | [10-K 2025-11-28] |
- Quarterly cash burn
- −$1.59M
- Cash runway Estimate
- ~6.6 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-25 | 17,452,594 | [10-K 2024-11-26] |
| 2025-01-10 | 17,552,594 | [10-Q 2025-01-10] |
| 2025-04-14 | 17,559,179 | [10-Q 2025-04-14] |
| 2025-07-11 | 19,559,179 | [10-Q 2025-07-14] |
| 2025-11-25 | 22,225,846 | [10-K 2025-11-28] |
| 2026-01-13 | 24,887,446 | [10-Q 2026-01-13] |
| 2026-04-13 | 24,787,446 | [10-Q 2026-04-13] |
| 2026-07-13 | 24,787,446 | [10-Q 2026-07-13] |
- Shelf registration
- S-3 filed 2026-10-02; no effectiveness notice found in EDGAR [S-3 2026-10-02]
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-08-10. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-08-10 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-08-10] |
| 2026-02-06 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-02-06] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-03-17 | Bunka Christopher | other | 100,000 | — | [4 2026-03-18] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-02 | S-3 | Registration statement |
| 2026-09-09 | 8-K | Material agreement entered; Unregistered sale of equity; Regulation FD disclosure |
| 2026-09-01 | 8-K | Other events |
| 2026-08-17 | 8-K | Other events |
| 2026-08-10 | 8-K | Listing notice or transfer |
| 2026-07-30 | 8-K | Change to security holder rights; Charter, bylaws or fiscal year change |
| 2026-07-13 | 10-Q | Quarterly report |
| 2026-04-13 | 10-Q | Quarterly report |
| 2026-02-06 | 8-K | Listing notice or transfer |
| 2026-01-28 | 8-K | Shareholder vote results |
| 2026-01-14 | 424B3 | Prospectus or prospectus supplement |
| 2026-01-13 | 10-Q | Quarterly report |
Alerts for $LEXX
Email me when Lexaria Bioscience Corp. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.